Journal Article

Therapeutic options for <i>Stenotrophomonas maltophilia</i> infections beyond co-trimoxazole: a systematic review

Matthew E. Falagas, Politimi-Eleni Valkimadi, Yu-Tsung Huang, Dimitrios K. Matthaiou and Po-Ren Hsueh

in Journal of Antimicrobial Chemotherapy

Published on behalf of British Society for Antimicrobial Chemotherapy

Volume 62, issue 5, pages 889-894
Published in print November 2008 | ISSN: 0305-7453
Published online July 2008 | e-ISSN: 1460-2091 | DOI: http://dx.doi.org/10.1093/jac/dkn301
Therapeutic options for Stenotrophomonas maltophilia infections beyond co-trimoxazole: a systematic review

More Like This

Show all results sharing these subjects:

  • Medical Oncology
  • Critical Care

GO

Show Summary Details

Preview

Background

Stenotrophomonas maltophilia has emerged as an important opportunistic pathogen, causing infections whose management is often problematic due to its inherent resistance to many antibiotics, making co-trimoxazole the main therapeutic option. However, there are cases in which either due to antimicrobial resistance or allergic reactions and intolerance to co-trimoxazole this antibiotic cannot be administered. We sought to evaluate the available clinical evidence regarding potentially effective alternative antibiotics for the treatment of S. maltophilia infections.

Methods

The literature search was performed in the PubMed and Scopus databases. The search string used was ‘Stenotrophomonas maltophilia OR Xanthomonas maltophilia'.

Results

Thirty-one case reports and 5 case series were retrieved including a total of 49 patients with a variety of infections. Twenty of 49 cases (40.8%) were treated with ciprofloxacin as monotherapy or in combination with other antibiotics; 12 of 49 cases (24.5%) were treated with ceftriaxone- or ceftazidime-based regimens; and 6 of 49 cases (12.2%) were treated with ticarcillin- or ticarcillin/clavulanate-based regimens. The cure or improvement rates were 18 cases (90%), 8 (75%) and 4 (66.7%), respectively. The remaining 11 patients received various antimicrobials including aminoglycoside-based regimens, carbapenems, levofloxacin, chloramphenicol, aztreonam, minocycline and other β-lactams.

Conclusions

The limited available data suggest that ciprofloxacin, ceftazidime or ceftriaxone, and ticarcillin/clavulanate, alone or in combination with other antibiotics, may be considered as alternative options beyond co-trimoxazole.

Keywords: ciprofloxacin; ceftazidime; ceftriaxone; antimicrobial resistance; ticarcillin/clavulanate; Xanthomonas; Pseudomonas

Journal Article.  3756 words. 

Subjects: Medical Oncology ; Critical Care

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.